Evidence map›Paper›PMID 19494806›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2009

Dopamine genes and nicotine dependence in treatment-seeking and community smokers.

Andrew W Bergen, David V Conti, David Van Den Berg, Wonho Lee, Jinghua Liu, Dalin Li, Nan Guo, Huaiyu Mi, Paul D Thomas, Christina N Lessov-Schlaggar and 11 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Association of CHRNA4 polymorphisms with smoking behavior in two populations.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2011
    Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Twin Research Registry at SRI International.Twin research and human genetics : the official journal of the International Society for Twin Studies · 2013
    Article
  15. Article
  16. Article
  17. Article
  18. PharmGKB summary: dopamine receptor D2.Pharmacogenetics and genomics · 2011
    Article
  19. Article
  20. Monoamine transporters: vulnerable and vital doorkeepers.Progress in molecular biology and translational science · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 2 countries.

Andrew W BergenCenter for Health Sciences, SRI International, Menlo Park, CA 94025, USA. andrew.bergen@sri.com
David V Conti
David Van Den Berg
Wonho Lee
Jinghua Liu
Dalin Li
Nan Guo
Huaiyu Mi
Paul D Thomas
Christina N Lessov-Schlaggar
Ruth Krasnow
Yungang He
Denise Nishita
Ruhong Jiang
Jennifer B McClure
Elizabeth Tildesley
Hyman Hops
Rachel F Tyndale
Neal L Benowitz
Caryn Lerman
Gary E Swan
SRI International · USUniversity of Southern California · USCentre for Addiction and Mental Health · CAEugene Research Institute · USGroup Health Cooperative · USOregon Research Institute · USUniversity of California, San Francisco · USUniversity of Pennsylvania · USWashington University in St. Louis · US

Funding

University of Toronto Coordinating Genetics Core & Clinical Trial SiteU01DA020830 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI BENOWITZ, NEAL L · 2005 to 2014
$22.4M
TRANSDISCIPLINARY TOBACCO USE RESEARCH CENTERP50CA084735 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JOHNSON, CARL ANDERSON · 1999 to 2008
$18.0M
TRANSDISCIPLINARY TOBACCO USE RESEARCH CENTERSP50CA084718 · NCI · UNIVERSITY OF PENNSYLVANIA · PI PERKINS, KENNETH ALAN · 1999 to 2008
$17.8M
Treatment of Nicotine Dependence in Health Care SettingR01CA071358 · NCI · SRI INTERNATIONAL · PI SWAN, GARY E · 1997 to 2009
$3.8M
BIOBEHAVIORAL LUNG CANCER PREVENTION PROGRAMR01CA063562 · NCI · UNIVERSITY OF PENNSYLVANIA · PI LERMAN, CARYN · 1993 to 2004
$2.7M
YOUNG ADULT SUBSTANCE USE--PREDICTORS AND CONSEQUENCESR01DA003706 · NIDA · OREGON RESEARCH INSTITUTE · PI HOPS, HYMAN · 1985 to 2002
$2.5M
Computational Methods for Fine MappingR01GM069890 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MARJORAM, PAUL · 2004 to 2007
$1.9M
NCI NIH HHS P50 CA084718NCI NIH HHS P50 CA084735NCI NIH HHS P50 CA84718NCI NIH HHS R01 CA063562NCI NIH HHS R01 CA071358NCI NIH HHS R01 CA63562NIDA NIH HHS R01 DA003706NIDA NIH HHS R01 DA03706NIDA NIH HHS U01 DA020830NIDA NIH HHS U01 DA020830-03NIGMS NIH HHS R01 GM069890
6 · The paper itself

Abstract

We utilized a cohort of 828 treatment-seeking self-identified white cigarette smokers (50% female) to rank candidate gene single nucleotide polymorphisms (SNPs) associated with the Fagerström Test for Nicotine Dependence (FTND), a measure of nicotine dependence which assesses quantity of cigarettes smoked and time- and place-dependent characteristics of the respondent's smoking behavior. A total of 1123 SNPs at 55 autosomal candidate genes, nicotinic acetylcholine receptors and genes involved in dopaminergic function, were tested for association to baseline FTND scores adjusted for age, depression, education, sex, and study site. SNP P-values were adjusted for the number of transmission models, the number of SNPs tested per candidate gene, and their intragenic correlation. DRD2, SLC6A3, and NR4A2 SNPs with adjusted P-values <0.10 were considered sufficiently noteworthy to justify further genetic, bioinformatic, and literature analyses. Each independent signal among the top-ranked SNPs accounted for approximately 1% of the FTND variance in this sample. The DRD2 SNP appears to represent a novel association with nicotine dependence. The SLC6A3 SNPs have previously been shown to be associated with SLC6A3 transcription or dopamine transporter density in vitro, in vivo, and ex vivo. Analysis of SLC6A3 and NR4A2 SNPs identified a statistically significant gene-gene interaction (P=0.001), consistent with in vitro evidence that the NR4A2 protein product (NURR1) regulates SLC6A3 transcription. A community cohort of N=175 multiplex ever-smoking pedigrees (N=423 ever smokers) provided nominal evidence for association with the FTND at these top ranked SNPs, uncorrected for multiple comparisons.

Indexed as

Genetic Predisposition to DiseaseResidence CharacteristicsAdultAnalysis of VarianceBupropionCohort StudiesDNA-Binding ProteinsDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsFemaleGenotypeHumansLinkage DisequilibriumMaleMiddle AgedNuclear Receptor Subfamily 4, Group A, Member 2BupropionDNA-Binding ProteinsDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsDRD3 protein, humanNR4A2 protein, humanNuclear Receptor Subfamily 4, Group A, Member 2Receptors, Dopamine D3SLC6A3 protein, humanTranscription Factors

Identifiers

PMID19494806
PMCPMC3558036
OpenAlexW1978005528

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.